Imunon (NASDAQ:IMNN) Given Buy Rating at D. Boral Capital

Imunon (NASDAQ:IMNN)‘s stock had its “buy” rating reiterated by stock analysts at D. Boral Capital in a note issued to investors on Monday,Benzinga reports. They presently have a $29.00 price objective on the stock.

IMNN has been the subject of several other reports. HC Wainwright cut their target price on shares of Imunon from $14.00 to $12.00 and set a “buy” rating for the company in a report on Monday, November 11th. EF Hutton Acquisition Co. I raised shares of Imunon to a “strong-buy” rating in a report on Monday, September 23rd.

Imunon Price Performance

NASDAQ:IMNN opened at $0.83 on Monday. The firm has a market cap of $12.02 million, a price-to-earnings ratio of -0.44 and a beta of 2.14. The company has a 50 day moving average price of $0.93 and a 200-day moving average price of $1.14. Imunon has a 1-year low of $0.48 and a 1-year high of $3.65.

Imunon Company Profile

Imunon, Inc, a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company’s lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development.